Experiences of treatment decision-making among older newly diagnosed adults with acute myeloid leukemia: a qualitative descriptive study-Reference-Cited by-同舟云学术

Experiences of treatment decision-making among older newly diagnosed adults with acute myeloid leukemia: a qualitative descriptive study

Published:2024-02-28 Issue:3 Volume:32 Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Richardson Daniel R.,Mhina Carl J.,Teal Randall,Cole Amy C.,Adapa Karthik,Bryant Ashley L.,Crossnohere Norah,Wheeler Stephanie C.,Bridges John F. P.,Wood William A.

Funder

Conquer Cancer Foundation

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00520-024-08397-3.pdf

Reference35 articles.

1. U. S. National Institutes of Health, National Cancer Institute (2019) Acute myeloid leukemia - cancer stat facts. In: Acute myeloid leukemia statistics. https://seer.cancer.gov/statfacts/html/amyl.html. Accessed 18 Nov 2018

2. Short NJ, Konopleva M, Kadia TM et al (2020) Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov 10(4):506–525. https://doi.org/10.1158/2159-8290.CD-19-1011

3. Sorror ML, Storer BE, Fathi AT et al (2021) Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood 138:387–400. https://doi.org/10.1182/blood.2020008812

4. Jensen CE, Heiling HM, Beke KE et al (2022) Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. Haematol. https://doi.org/10.3324/haematol.2022.280728

5. Richardson DR, Zhou X, Jensen CE et al (2022) Time at home among older adults with acute myeloid leukemia based on treatment intensity: a SEER-Medicare analysis. JCO 40:6586–6586. https://doi.org/10.1200/JCO.2022.40.16_suppl.6586

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zelluläre Therapien im Alter: Everything, everywhere, all at once?;InFo Hämatologie + Onkologie;2024-07